Apr. 27 at 11:29 PM
While investing is a marathon & not a sprint, 2 of 3 commercial-stage oncology focused bios traded lower today again while the
$XBI was more or less flat.
$SNDX has traded lower 6 of the last 7 trading sessions & is now off 13% from 2 Friday's ago.
$INCY reports Niktimvo sales tomorrow morning. This is as potentially impactful to SNDX valuation as it gets. Otherwise, recall SNDX said they expect to record Niktimvo collaboration revenues at roughly 30% of sales. SNDX reports Revuforj sales Thursday after the close.
$VSTM was off again today. VSTM's LGSOC combo sales have, and is expected to, track to or slightly above Vonjo's launch (especially if analyst estimates are credible). Vonjo was acquired for
$1.7B. VSTM's fully diluted enterprise value is a hair over
$400MM with a 7375 read expected this quarter. Absent VSTM management shenanigans, VSTM's risk v reward profile appears compelling.
$NUVB was off 7% today. We're unaware of any news or inflection point. NUVB reports Q126 on 5/4/26
